FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR The team tackling the serious side effects of cancer treatment in... August 19, 2020 FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or... December 2, 2021 Is there a future without Pap testing? October 21, 2020 ESMO Congress 2021, 16-21 September September 2, 2021 Load more HOT NEWS Registered Dietitian vs. Nutritionist ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... FDA Approves New Interchangeable Biosimilar to Pertuzumab ESMO Congress 2021, 16-21 September
